



Hemogenyx Pharmaceuticals plc

30 June 2020

Hemogenyx Pharmaceuticals plc
(the "Company")

Director/PDMR Shareholding

Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), and his wife, Olena Wright, have purchased a total of 434,704 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at an average price of 5.76p per share. Following this transaction, Mr Wright has a total beneficial interest in 1,532,109 Ordinary Shares, representing approximately 0.35 per cent of the Company's issued share capital.

Market Abuse Regulation (MAR) Disclosure

Certain information contained in this announcement would have been deemed inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 until the release of this announcement.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1.	Details of PDMR/person closely associated with them ("PCA")	
a)	Name	Andrew Wright
b)	Position/status	PDMR: Financial Controller and Company Secretary
c)	Initial notification/ amendment	Initial notification
2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	

a)	Description of the financial instrument	Ordinary shares of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24	
b)	Nature of the transaction	Standalone acquisition of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		GBP £0.056799	90,554
d)	Aggregated information - Aggregated volume - Price	Price(s)	Volume(s)
		GBP £5,143.38	90,554
e)	Date of the transaction	2020-06-29	
f)	Place of the transaction	London Stock Exchange XLON	

1.	Details of PDMR/person closely associated with them ("PCA")		
a)	Name	Olena Wright	
b)	Position/status	PCA: Spouse of Andrew Wright (PDMR: Financial Controller and Company Secretary)	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument	Ordinary shares of Hemogenyx Pharmaceuticals plc Identification code GB00BYX3WZ24	
b)	Nature of the transaction	Standalone acquisition of shares	
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		GBP £0.057799	344,150

d)	Aggregated information - Aggregated volume - Price	Price(s)		Volume(s)	
		GBP £19,891.53		344,150	
e)	Date of the transaction	2020-06-29			
f)	Place of the transaction	London Stock Exchange XLON			

Enquiries:

Hemogenyx Pharmaceuticals plc

hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

headquarters@hemogenyx.com

Peter Redmond, Director

SP Angel Corporate Finance LLP

Tel: +44 (0)20 3470 0470

Matthew Johnson, Vadim Alexandre, Soltan Tagiev

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey

US Media enquiries

Tel: +1 (323) 646-3249

Lowell Goodman

lowell@corbomitecomms.com